Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 963-969

  Krishna, Gopal ^a   Kisicki, James C ^b   Olsen, Steven ^c   Grasela, Dennis M ^c   Wang, Zaiqi ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MDS Inc   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bioavailability; Chelating agents; Garenoxacin; Maalox; Quinolones

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; GARENOXACIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FEMALE; HEMATOCHEZIA; HUMAN; HUMAN EXPERIMENT; MALE; METHODOLOGY; NAUSEA; NORMAL HUMAN; OPEN STUDY; PAIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL EFFECTS DESIGN; VOLUNTEER;

ADULT; ALUMINUM HYDROXIDE; ANTACIDS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MAGNESIUM HYDROXIDE; MALE;

EID: 34250888629     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.963     Document Type: Article

References (20)

1. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766-77.
2. Azoulay-Dupuis E, Bedos JP, Mohler J, et al. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob Agents Chemother 2004;48:765-73.
3. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589-92.
4. Jones RN, Biedenbach DJ. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY antimicrobial surveillance program (1999-2001). Diagn Microbiol Infect Dis 2003;45:273-8.
5. Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities. Antimicrob Agents Chemother 2003;47: 3539-41.
6. Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256-63.
7. Stewart C, Gajjar D, Bello A, et al. Safety, tolerability and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following 28 days of once-daily oral dosing in healthy subjects [abstract]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2001:8.
8. Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51:727-30.
9. Gajjar D, Geraldes M, Russo R, Bello A, Christopher L, Grasela D. Lack of effect of intravenous BMS-284756 on the QTc interval in healthy subjects [abstract]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American society for Microbiology, 2001:19.
10. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy 1999;45:504-11.
11. Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. Clin Ther 1998;20:1149-58.
12. Marshall AJ, Piddock LJ. Interaction of divalent cations, quinolones and bacteria. J Antimicrob Chemother 1994;34:465-83.
13. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-5.
14. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992;36:2270-4.
15. Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother 1992;36:1219-24.
16. Tanaka M, Kurata T, Fujisawa C, et al. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob Agents Chemother 1993;37:2173-8.
17. Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. DICP 1991;25:1249-58.
18. Toussaint B, Chedin M, Bordin G, Rodriguez AR. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography-tandem mass spectrometry. I. Laboratory-validated method. J Chromatogr A 2005;1088:32-9.
19. Toussaint B, Chedin M, Vincent U, Bordin G, Rodriguez AR. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography-tandem mass spectrometry. II. Intercomparison exercise. J Chromatogr A 2005;1088:40-8.
20. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.